MDP Insider Trading

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): C$11,900.00
Insider Selling (Last 12 Months): C$0.00

Medexus Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Medexus Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Medexus Pharmaceuticals Share Price & Price History

Current Price: C$7.75
Price Change: Price Decrease of -0.4 (-4.91%)
As of 06/16/2021 01:00 AM ET

This chart shows the closing price history over time for MDP up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Medexus Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/21/2022Kenneth D'entremontDirectorBuy10,000C$1.19C$11,900.00592,057
9/24/2021Roland BoivinSenior OfficerBuy3,033C$2.97C$9,008.0120,928
9/23/2021Kenneth D'entremontDirectorBuy5,000C$3.00C$15,000.00353,567
8/19/2021Roland BoivinSenior OfficerBuy500C$2.77C$1,385.0013,395
6/25/2021Glenn TateDirectorBuy2,600C$7.81C$20,315.3839,634
6/21/2021Roland BoivinSenior OfficerBuy500C$7.20C$3,600.0012,095
See Full Table

SEC Filings (Institutional Ownership Changes) for Medexus Pharmaceuticals (CVE:MDP)

Medexus Pharmaceuticals logo
Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, which is indicated for the treatment of seasonal allergic rhinitis, perennial allergic rhinitis, and chronic spontaneous urticaria in patients 2 years of age and older. Its products portfolio also include Cuvposa, which is indicated for sialorrhea in patients aged 3-18 years with neurologic conditions, such as cerebral; Gliolan, an orally administered drug used for the visualization of various brain tumors; and Treosulfan, a conditioning agent used prior to stem cell transplantation. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Verdun, Canada.
Read More on Medexus Pharmaceuticals

Today's Range

Now: C$7.75
Low: C$7.70
High: C$8.14

50 Day Range

MA: C$7.75
Low: C$7.75
High: C$7.75

52 Week Range

Now: C$7.75
Low: C$2.80
High: C$9.75

Volume

40,981 shs

Average Volume

68,619 shs

Market Capitalization

C$148.54 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Medexus Pharmaceuticals?

Medexus Pharmaceuticals' top insider investors include:
  1. Kenneth D'entremont (Director)
  2. Glenn Tate (Director)
  3. Roland Boivin (Senior Officer)
Learn More about top insider investors at Medexus Pharmaceuticals.